Guidance for healthcare professionals on risk minimisation options for medicines.
Similar Posts
Decision: Advertising Investigations: January 2026
Decisions made by the MHRA following investigations into complaints about advertising for licensed medicines.
Class 4 Medicines Defect Notification: Olmesartan medoxomil 10mg film-coated tablets, Jubilant Pharmaceuticals NV, EL(25)A/37
Jubilant Pharmaceuticals NV has informed the MHRA that the Patient Information leaflet (PIL) in the cartons for the batches listed in this notification include an outdated PIL.
Cutting-edge personalised treatments, made while you wait, will deliver specialised care to patients more quickly
New regulations effective today will make it faster and easier for cutting-edge cancer treatments and personalised gene therapies to be made right where patients are treated.
Decision: Advertising Investigations: December 2025
Decisions made by the MHRA following investigations into complaints about advertising for licensed medicines.
MHRA Safety Roundup: May 2025
Summary of the latest safety advice for medicines and medical device users
Guidance: Human medicines Modular Manufacture and Point of Care regulations 2025: Overview
Helping interpret the Human Medicines (Amendment) Modular Manufacture and Point of Care regulations 2025.